Sandra Calvin Travere Therapeutics, Inc. (TVTX) insider trading activity

Sandra Calvin is SVP, CHIEF ACCOUNTING OFFICER of Travere Therapeutics, Inc.. Currently has a direct ownership of 54,410 shares of TVTX, which is worth approximately $1.2 Million. The most recent transaction as insider was on Feb 11, 2025, when has been sold 54,244 shares (Common Stock) at a price of $25.0 per share, resulting in proceeds of $1,356,100. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 54.4K

4.6% 3M change

4.6% 12M change

Total Value Held $1.2 Million

Sandra Calvin Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 11 2025	SELL Open market or private sale	$1,356,100 $25.0 p/Share	54,244 Reduced 49.92%	54,410 Common Stock
Feb 11 2025	BUY Exercise of conversion of derivative security	$754,650 $16.77 p/Share	45,000 Added 36.39%	78,654 Common Stock
Feb 03 2025	SELL Open market or private sale	$67,361 $20.12 p/Share	3,348 Reduced 5.0%	63,654 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	13,000 Added 16.25%	67,002 Common Stock
Jan 22 2025	SELL Open market or private sale	$17,519 $18.94 p/Share	925 Reduced 1.68%	54,002 Common Stock
Dec 26 2024	SELL Open market or private sale	$258,299 $17.22 p/Share	15,000 Reduced 21.45%	54,927 Common Stock
Dec 26 2024	BUY Exercise of conversion of derivative security	$190,050 $12.67 p/Share	15,000 Added 17.66%	69,927 Common Stock
Nov 25 2024	SELL Open market or private sale	$221,247 $18.3 p/Share	12,090 Reduced 18.04%	54,927 Common Stock
Nov 25 2024	BUY Exercise of conversion of derivative security	$190,050 $12.67 p/Share	15,000 Added 18.29%	67,017 Common Stock
Feb 01 2024	SELL Open market or private sale	$24,054 $8.53 p/Share	2,820 Reduced 5.14%	52,017 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	13,500 Added 19.76%	54,837 Common Stock
Jan 23 2024	SELL Open market or private sale	$8,253 $9.07 p/Share	910 Reduced 2.15%	41,337 Common Stock
May 11 2023	SELL Open market or private sale	$1,966 $16.12 p/Share	122 Reduced 0.29%	42,247 Common Stock
May 10 2023	SELL Open market or private sale	$7,233 $16.59 p/Share	436 Reduced 1.02%	42,369 Common Stock
Feb 02 2023	SELL Open market or private sale	$8,071 $22.42 p/Share	360 Reduced 0.83%	42,805 Common Stock
Feb 01 2023	SELL Open market or private sale	$36,344 $21.75 p/Share	1,671 Reduced 3.73%	43,165 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	10,000 Added 18.24%	44,836 Common Stock
Jan 25 2023	SELL Open market or private sale	$4,152 $21.63 p/Share	192 Reduced 0.55%	34,836 Common Stock
Jan 24 2023	SELL Open market or private sale	$19,819 $21.9 p/Share	905 Reduced 2.52%	35,028 Common Stock
Sep 13 2022	SELL Open market or private sale	$9,772 $28.0 p/Share	349 Reduced 0.96%	35,933 Common Stock
May 11 2022	SELL Open market or private sale	$9,754 $21.92 p/Share	445 Reduced 1.23%	35,733 Common Stock
May 10 2022	SELL Open market or private sale	$9,378 $21.51 p/Share	436 Reduced 1.19%	36,178 Common Stock
Jan 31 2022	SELL Open market or private sale	$21,155 $26.51 p/Share	798 Reduced 2.13%	36,614 Common Stock
Jan 31 2022	BUY Grant, award, or other acquisition	-	8,750 Added 18.95%	37,412 Common Stock
Jan 24 2022	SELL Open market or private sale	$22,958 $24.58 p/Share	934 Reduced 3.16%	28,662 Common Stock

Sandra Calvin

SVP, CHIEF ACCOUNTING OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Value

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Travere Therapeutics, Inc.

Track Activities on TVTX

Account